×

Kraig Biocraft Laboratories Announces That the First Stage of Its Pilot Production Program Has Resulted in Monster Silk(TM) Cocoons

LANSING, Mich., March 4, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the silkworm hatchlings from the first stage of its Monster Silk™ pilot production program ("program") have now spun cocoons. The cocoons are made of Monster Silk™, the Company's recombinant spider silk.

The program is running in three stages, with stage 1 being the first of the production stages to produce Monster Silk™ cocoons. Stage 2 of the program is now entering a very advanced state. All three stages are ahead of schedule and are hitting or exceeding their milestones.

"Our focus on innovation and scientific excellence is transitioning well from the laboratory to production, and this ambitious pilot production program is designed to test our systems and to become the basis for large commercial scale production," said Company founder and CEO, Kim K. Thompson.

"The pilot production program goals included confirming Monster Silk's™ production scalability; to get these results so smoothly is a tremendous boost the Company's expansion plans."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com

Source:Kraig Biocraft Laboratories, Inc